Management of Exercise-Induced Tachycardia in Patients with Atrial Fibrillation

Initial Assessment and Rate Control Strategy

The European Society of Cardiology recommends assessment of heart rate control during exercise and adjustment of pharmacological treatment to keep the rate in the physiological range as first-line management for patients with atrial fibrillation experiencing exercise-induced tachycardia 1, 2, 3
Assessment of heart rate response to submaximal or maximal exercise is essential to evaluate the adequacy of rate control in patients with atrial fibrillation 4
A tailored exercise program is recommended to improve cardiorespiratory fitness and reduce atrial fibrillation recurrence in patients with atrial fibrillation and rapid ventricular response during exercise 1
Beta-blockers are the first-line pharmacological therapy for controlling exercise-induced tachycardia in atrial fibrillation patients, particularly in those with preserved ejection fraction 5, 2
For patients with heart failure with preserved ejection fraction, a nondihydropyridine calcium channel antagonist can be used as an alternative to beta-blockers 2, 6

A combination of digoxin and a beta-blocker (or a nondihydropyridine calcium channel antagonist for patients with heart failure with preserved ejection fraction) is reasonable to control both resting and exercise heart rate in patients with atrial fibrillation 5, 2, 6
When resting and exercise heart rate cannot be adequately controlled using a beta-blocker or nondihydropyridine calcium channel antagonist alone or in combination with digoxin, oral amiodarone may be considered 2, 7
For patients with atrial fibrillation and rapid ventricular response causing or suspected of causing tachycardia-induced cardiomyopathy, it is reasonable to achieve rate control by either AV nodal blockade or a rhythm-control strategy 2, 6

If pharmacological therapy is insufficient or not tolerated, AV node ablation with ventricular pacing is reasonable to control heart rate 5, 2
AV node ablation may be considered when the rate cannot be controlled and tachycardia-mediated cardiomyopathy is suspected, but should not be performed without a prior pharmacological trial 2, 6
For patients with chronic heart failure who remain symptomatic from atrial fibrillation despite a rate-control strategy, a rhythm-control strategy is reasonable 2, 6
Catheter ablation is recommended as a first-line option within a shared decision-making rhythm control strategy in patients with paroxysmal atrial fibrillation to reduce symptoms, recurrence, and progression of atrial fibrillation 1

A tailored exercise program is recommended in individuals with paroxysmal or persistent atrial fibrillation to improve cardiorespiratory fitness and reduce atrial fibrillation recurrence 1
Weight loss is recommended as part of comprehensive risk factor management in overweight and obese individuals with atrial fibrillation to reduce symptoms and atrial fibrillation burden, with a target of 10% or more reduction in body weight 1
Reducing alcohol consumption to ≤3 standard drinks (≤30 grams of alcohol) per week is recommended to reduce atrial fibrillation recurrence 1

Regular assessment of heart rate control during exercise and adjustment of pharmacological treatment is essential for symptomatic patients during activity 2, 3
Consider using 24-hour Holter monitoring to evaluate heart rate response over an extended period 4
For patients with atrial fibrillation and rapid ventricular response causing or suspected of causing tachycardia-induced cardiomyopathy, close monitoring and aggressive management are warranted 2, 6